Antiproliferative and Recovery Effects During Treatment of Breast and Ovarian Carcinoma Cell Cultures with Interferon-γ

Klouche, Mariam; Kirchner, Holger; Hölzel, F.

doi:10.1089/jir.1995.15.285

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Als Monotherapie weist IFN-a bei soliden Tumoren nur eine begrenzte Wirksamkeit auf und kommt eher für die Kombinationstherapie mit anderen BRM (biologische Response-Modifier) oder konventionellen Chemotherapeutika in Frage. Ein wichtiges Problem bei der Behandlung mit Interferonen liegt, wie am humanen Zellkulturmodell gezeigt wurde, in der Resistenzentwicklung der Tumorzellen oder sogar in der Entwicklung einer paradoxen Wachstumsförderung, die auch durch Kombinationstherapien nicht immer verhindert werden kann [26,27].…”

Section: Zytokineunclassified

Zytokine

Klouche¹

2003

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschu

View full text Add to dashboard Cite

Cytokines are highly efficient mediators of the immune system, which are active in nano-to picomolar concentrations.In the past 35 years, new cytokines and entire cytokine families have been discovered, which are tightly connected in the cytokine network.Cytokines regulate basic biologic processes, including the co-ordination of immune and inflammatory reactions, as well as the regulation of haematopoiesis, of repair processes and of development.While cytokines form the basis of the co-ordinated immune surveillance against developing tumours, and suppress the proliferation and the metastasis of established malignancies, cytokines may also act as autocrine or paracrine growth factors for tumours and exert tumour-promoting generalised immunosuppressive effects.Despite the broad spectrum of activity, and the increasing knowledge of the molecular pathways of cytokine action, the identification of suitable therapeutic targets is not trivial.It is therefore not surprising, that the therapeutic applications of cytokines are currently restricted to only few tumour entities.Besides the treatment with recombinant cytokines,cytokine inducers and cytokine antagonists, the semisynthetic fusion proteins (designer-cytokines) and particularly the cell-based therapies open promising innovative therapeutic perspectives.

show abstract

Section: Zytokineunclassified

Zytokine

Klouche¹

2003

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschu

View full text Add to dashboard Cite

show abstract

IFN-γ-Induced Change in Microtubule Organization and α-Tubulin Expression During Growth Inhibition of Lung Squamous Carcinoma Cells

Everding

Wilhelm

Averesch

et al. 2000

Journal of Interferon & Cytokine Research

View full text Add to dashboard Cite

In cultures of KNS-62 cells derived from a human lung squamous cell carcinoma, the initial growth arrest in the continuous presence of interferon-gamma (IFN-gamma) turned to cytopathic effects after 2 days of treatment. The remaining viable cells showed grossly distorted morphology, with enlargement and extensions up to 5 cell diameters. The presence of apoptotic cells was shown 3 days after treatment with IFN-gamma. Immunocytochemically, the microtubular structures appeared augmented and highly aggregated. The level of alpha-tubulin-specific mRNA was distinctly increased after administration of IFN-gamma, and the amount of extractable alpha-tubulin protein was reduced. In parallel kinetics experiments, growth arrest by serum depletion or by contact inhibition during confluence resulted in reduced levels of alpha-tubulin-specific mRNA and in slightly elevated alpha-tubulin protein. The IFN-gamma-induced effects suggest interference with assembly or maintenance of the tubulin cable network, presumably associated with cell deformation and cytotoxicity.

show abstract

A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses

Dakappagari

Pyles

Parihar³

et al. 2003

The Journal of Immunology

View full text Add to dashboard Cite

Immunotherapeutic approaches to cancer should focus on novel undertakings that modulate immune responses by synergistic enhancement of antitumor immunological parameters. Cancer vaccines should preferably be composed of multiple defined tumor Ag-specific B and T cell epitopes. To develop a multiepitope vaccine, 12 high ranking B cell epitopes were identified from the extracellular domain of the human epidermal growth factor receptor-2 (HER-2) oncoprotein by computer-aided analysis. Four novel HER-2 B cell epitopes were synthesized as chimeras with a promiscuous T cell epitope (aa 288–302) from the measles virus fusion protein (MVF). Two chimeric peptide vaccines, MVF HER-2316–339 and MVF HER-2485–503 induced high levels of Abs in outbred rabbits, which inhibited tumor cell growth. In addition, Abs induced by a combination of two vaccines, MVF HER-2316–339 and MVF HER-2628–647 down-modulated receptor expression and activated IFN-γ release better than the individual vaccines. Furthermore, this multiepitope vaccine in combination with IL-12 caused a significant reduction (p = 0.004) in the number of pulmonary metastases induced by challenge with syngeneic tumor cells overexpressing HER-2. Peptide Abs targeting specific sites in the extracellular domain may be used for exploring the oncoprotein’s functions. The multiepitope vaccine may have potential application in the treatment of HER-2-associated cancers.

show abstract

Antiproliferative and Recovery Effects During Treatment of Breast and Ovarian Carcinoma Cell Cultures with Interferon-γ

Cited by 3 publications

References 24 publications

Zytokine

Zytokine

IFN-γ-Induced Change in Microtubule Organization and α-Tubulin Expression During Growth Inhibition of Lung Squamous Carcinoma Cells

A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses

Contact Info

Product

Resources

About